Cyclic Nucleotide Phosphodiesterases, Type 5
"Cyclic Nucleotide Phosphodiesterases, Type 5" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cyclic nucleotide phosphodiesterase subfamily that is highly specific for CYCLIC GMP. It is found predominantly in vascular tissue and plays an important role in regulating VASCULAR SMOOTH MUSCLE contraction.
Descriptor ID |
D054706
|
MeSH Number(s) |
D08.811.277.352.640.150.500 D08.811.277.352.640.155.500 D12.644.360.008.500 D12.644.360.009.500 D12.776.476.008.500 D12.776.476.009.500
|
Concept/Terms |
Cyclic Nucleotide Phosphodiesterases, Type 5- Cyclic Nucleotide Phosphodiesterases, Type 5
- Phosphodiesterase 5A, cGMP-Specific
- Phosphodiesterase 5A, cGMP Specific
- cGMP-Specific Phosphodiesterase 5A
- Phosphodiesterase 5A
- Phosphodiesterase Type 5
- Type 5, Phosphodiesterase
- Phosphodiesterase 5
- Phosphodiesterase-5
- Phosphodiesterase V
- cGMP-Binding, cGMP-Specific 3',5'-cyclic Nucleotide Phosphodiesterase
- PDE5 Phosphodiesterases
- Phosphodiesterases, PDE5
- Phosphodiesterase Type V
- Type V, Phosphodiesterase
|
Below are MeSH descriptors whose meaning is more general than "Cyclic Nucleotide Phosphodiesterases, Type 5".
- Chemicals and Drugs [D]
- Enzymes and Coenzymes [D08]
- Enzymes [D08.811]
- Hydrolases [D08.811.277]
- Esterases [D08.811.277.352]
- Phosphoric Diester Hydrolases [D08.811.277.352.640]
- 3',5'-Cyclic-AMP Phosphodiesterases [D08.811.277.352.640.150]
- Cyclic Nucleotide Phosphodiesterases, Type 5 [D08.811.277.352.640.150.500]
- 3',5'-Cyclic-GMP Phosphodiesterases [D08.811.277.352.640.155]
- Cyclic Nucleotide Phosphodiesterases, Type 5 [D08.811.277.352.640.155.500]
- Amino Acids, Peptides, and Proteins [D12]
- Peptides [D12.644]
- Intracellular Signaling Peptides and Proteins [D12.644.360]
- 3',5'-Cyclic-AMP Phosphodiesterases [D12.644.360.008]
- Cyclic Nucleotide Phosphodiesterases, Type 5 [D12.644.360.008.500]
- 3',5'-Cyclic-GMP Phosphodiesterases [D12.644.360.009]
- Cyclic Nucleotide Phosphodiesterases, Type 5 [D12.644.360.009.500]
- Proteins [D12.776]
- Intracellular Signaling Peptides and Proteins [D12.776.476]
- 3',5'-Cyclic-AMP Phosphodiesterases [D12.776.476.008]
- Cyclic Nucleotide Phosphodiesterases, Type 5 [D12.776.476.008.500]
- 3',5'-Cyclic-GMP Phosphodiesterases [D12.776.476.009]
- Cyclic Nucleotide Phosphodiesterases, Type 5 [D12.776.476.009.500]
Below are MeSH descriptors whose meaning is more specific than "Cyclic Nucleotide Phosphodiesterases, Type 5".
This graph shows the total number of publications written about "Cyclic Nucleotide Phosphodiesterases, Type 5" by people in this website by year, and whether "Cyclic Nucleotide Phosphodiesterases, Type 5" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2007 | 1 | 1 | 2 |
2010 | 1 | 0 | 1 |
2019 | 0 | 1 | 1 |
2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cyclic Nucleotide Phosphodiesterases, Type 5" by people in Profiles.
-
Comparison of critical biomarkers in 2 erectile dysfunction models based on GEO and NOS-cGMP-PDE5 pathway. Medicine (Baltimore). 2021 Oct 15; 100(41):e27508.
-
Exogenous l-ARGININE does not stimulate production OF NO or cGMP within the rat corporal smooth muscle cells in culture. Nitric Oxide. 2019 08 01; 89:64-70.
-
Treatment of Peyronie's disease with PDE5 inhibitors: an antifibrotic strategy. Nat Rev Urol. 2010 Apr; 7(4):215-21.
-
Rationale for phosphodiesterase 5 inhibitor use post-radical prostatectomy: experimental and clinical review. Int J Impot Res. 2008 Jan-Feb; 20(1):30-4.
-
Long-term continuous treatment with sildenafil ameliorates aging-related erectile dysfunction and the underlying corporal fibrosis in the rat. Biol Reprod. 2007 May; 76(5):915-23.